These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 31762822)

  • 1. Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin.
    Peng Y; Wang L; Wu L; Zhang L; Nie G; Guo M
    J Cancer; 2019; 10(24):6124-6134. PubMed ID: 31762822
    [No Abstract]   [Full Text] [Related]  

  • 2. Epigenetic silencing schlafen-11 sensitizes esophageal cancer to ATM inhibitor.
    Zhou J; Zhang MY; Gao AA; Zhu C; He T; Herman JG; Guo MZ
    World J Gastrointest Oncol; 2024 May; 16(5):2060-2073. PubMed ID: 38764821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells.
    König P; Eichhorn JM; Suparman E; Bückreiß N; Cinatl J; Michaelis M; Bendas G
    Biochim Biophys Acta Mol Basis Dis; 2024 Dec; 1870(8):167448. PubMed ID: 39117290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors.
    Kaur S; Schwartz AL; Jordan DG; Soto-Pantoja DR; Kuo B; Elkahloun AG; Mathews Griner L; Thomas CJ; Ferrer M; Thomas A; Tang SW; Rajapakse VN; Pommier Y; Roberts DD
    Front Oncol; 2019; 9():994. PubMed ID: 31632920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse Slfn8 and Slfn9 genes complement human cells lacking SLFN11 during the replication stress response.
    Alvi E; Mochizuki AL; Katsuki Y; Ogawa M; Qi F; Okamoto Y; Takata M; Mu A
    Commun Biol; 2023 Oct; 6(1):1038. PubMed ID: 37833372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
    Conteduca V; Ku SY; Puca L; Slade M; Fernandez L; Hess J; Bareja R; Vlachostergios PJ; Sigouros M; Mosquera JM; Sboner A; Nanus DM; Elemento O; Dittamore R; Tagawa ST; Beltran H
    Mol Cancer Ther; 2020 May; 19(5):1157-1164. PubMed ID: 32127465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy.
    Kagami T; Yamade M; Suzuki T; Uotani T; Tani S; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Baba S; Sugimura H; Murai J; Pommier Y; Furuta T
    BMC Cancer; 2020 Nov; 20(1):1123. PubMed ID: 33218331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SLFN11 promotes stalled fork degradation that underlies the phenotype in Fanconi anemia cells.
    Okamoto Y; Abe M; Mu A; Tempaku Y; Rogers CB; Mochizuki AL; Katsuki Y; Kanemaki MT; Takaori-Kondo A; Sobeck A; Bielinsky AK; Takata M
    Blood; 2021 Jan; 137(3):336-348. PubMed ID: 32735670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress.
    Murai J; Zhang H; Pongor L; Tang SW; Jo U; Moribe F; Ma Y; Tomita M; Pommier Y
    Cell Rep; 2020 Mar; 30(12):4137-4151.e6. PubMed ID: 32209474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.
    Hu Y; Guo M
    Cancer Sci; 2020 Sep; 111(9):3111-3121. PubMed ID: 32639661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant NSUN2-mediated m
    Sun Z; Xue S; Zhang M; Xu H; Hu X; Chen S; Liu Y; Guo M; Cui H
    Oncogene; 2020 Nov; 39(45):6906-6919. PubMed ID: 32978516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing of IGFBPL1 promotes esophageal cancer growth by activating PI3K-AKT signaling.
    Liu Y; Zhang M; He T; Yang W; Wang L; Zhang L; Guo M
    Clin Epigenetics; 2020 Feb; 12(1):22. PubMed ID: 32041673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic based synthetic lethal strategies in human cancers.
    Gao A; Guo M
    Biomark Res; 2020; 8():44. PubMed ID: 32974031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
    Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
    Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
    Winkler C; Armenia J; Jones GN; Tobalina L; Sale MJ; Petreus T; Baird T; Serra V; Wang AT; Lau A; Garnett MJ; Jaaks P; Coker EA; Pierce AJ; O'Connor MJ; Leo E
    Br J Cancer; 2021 Mar; 124(5):951-962. PubMed ID: 33339894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response.
    Coleman N; Zhang B; Byers LA; Yap TA
    Br J Cancer; 2021 Mar; 124(5):857-859. PubMed ID: 33328609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway.
    Zhou C; Liu C; Liu W; Chen W; Yin Y; Li CW; Hsu JL; Sun J; Zhou Q; Li H; Hu B; Fu P; Atyah M; Ma Q; Xu Y; Dong Q; Hung MC; Ren N
    Theranostics; 2020; 10(10):4627-4643. PubMed ID: 32292519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of SLFN11 induces changes in DNA Damage response in breast cancer.
    Raynaud CM; Ahmed EI; Jabeen A; Sanchez A; Sherif S; Carneiro-Lobo TC; Awad A; Awartani D; Naik A; Thomas R; Decock J; Zoppoli G; Bedongnetti D; Hendrickx WRL
    Cancer Cell Int; 2023 Nov; 23(1):291. PubMed ID: 38001424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA Damage Repair and Current Therapeutic Approaches in Gastric Cancer: A Comprehensive Review.
    Wang M; Xie C
    Front Genet; 2022; 13():931866. PubMed ID: 36035159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?
    Tavares NT; Gumauskaitė S; Lobo J; Jerónimo C; Henrique R
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.